{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu B"],"funding":["This research was funded by the Zhejiang Medicine and Health Science and Technology Project","This research was granted by Scientific Research Project of Department of Education of Zhejiang Province"],"pagination":["659"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12265229"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Novel oral anticoagulants (NOACs), including rivaroxaban, apixaban, edoxaban and dabigatran, are increasingly used for orthopaedic surgery patients. The aim of this study was to evaluate the efficacy and safety of NOACs in preventing venous thromboembolism (VTE) among patients with lower limb fractures.<h4>Materials and methods</h4>This meta-analysis included randomized controlled trials (RCTs). The PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched from inception to November 27, 2024. We evaluated the risk of bias via the Cochrane Risk of Bias Tool 2.0 (RoB 2.0). The efficacy outcomes focused on VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE), and the safety outcomes focused on major bleeding events. Two researchers"],"journal":["Journal of orthopaedic surgery and research"],"pubmed_title":["NOACs for VTE prevention in patients with lower limb fracture: a systematic review and meta-analysis."],"pmcid":["PMC12265229"],"funding_grant_id":["NO.2025KY945","NO.Y202454954"],"pubmed_authors":["Sun L","Cao J","Wu B","Chen Y","Yan C","Wu W"],"additional_accession":[]},"is_claimable":false,"name":"NOACs for VTE prevention in patients with lower limb fracture: a systematic review and meta-analysis.","description":"<h4>Background</h4>Novel oral anticoagulants (NOACs), including rivaroxaban, apixaban, edoxaban and dabigatran, are increasingly used for orthopaedic surgery patients. The aim of this study was to evaluate the efficacy and safety of NOACs in preventing venous thromboembolism (VTE) among patients with lower limb fractures.<h4>Materials and methods</h4>This meta-analysis included randomized controlled trials (RCTs). The PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched from inception to November 27, 2024. We evaluated the risk of bias via the Cochrane Risk of Bias Tool 2.0 (RoB 2.0). The efficacy outcomes focused on VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE), and the safety outcomes focused on major bleeding events. Two researchers","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-03T10:16:06.108Z","creation":"2025-08-14T03:05:35.343Z"},"accession":"S-EPMC12265229","cross_references":{"pubmed":["40665327"],"doi":["10.1186/s13018-025-06092-5"]}}